DelveInsight's 'Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology report gives a thorough understanding of the Tenosynovial Giant Cell Tumors (TSGCTs) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Tenosynovial Giant Cell Tumors (TSGCTs) in the US, Europe, and Japan. The report covers the detailed information of the Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology scenario in seven major countries (US, EU5, and Japan).
The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology covered in the report provides historical as well as forecasted Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Tenosynovial Giant Cell Tumors (TSGCTs) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Tenosynovial Giant Cell Tumors (TSGCTs)
3. Tenosynovial Giant Cell Tumors (TSGCTs): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Tenosynovial Giant Cell Tumors (TSGCTs) Treatment and Management
6.2. Tenosynovial Giant Cell Tumors (TSGCTs) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in 7MM (2017-2030)
Table 2 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in the United States (2017-2030)
Table 4 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Germany (2017-2030)
Table 6 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in France (2017-2030)
Table 8 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Italy (2017-2030)
Table 10 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Spain (2017-2030)
Table 12 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in the United Kingdom (2017-2030)
Table 14 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Japan (2017-2030)
Table 16 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in 7MM (2017-2030)
Figure 2 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in the United States (2017-2030)
Figure 4 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Germany (2017-2030)
Figure 6 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in France (2017-2030)
Figure 8 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Italy (2017-2030)
Figure 10 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Spain (2017-2030)
Figure 12 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in the United Kingdom (2017-2030)
Figure 14 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology in Japan (2017-2030)
Figure 16 Tenosynovial Giant Cell Tumors (TSGCTs) Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
